Inhibikase Therapeutics Inc. – Filings and Transcripts

NASDAQ: IKT
Share price (5/22/26): $1.69
Market cap (5/22/26): $223 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Shelf registration

Ownership Filter

Commodore Capital LP

Trails Edge Capital Partners, LP

Perceptive Advisors LLC

ADAR1 Capital Management, LLC

Aurentz Vincent

News Filter

Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Announces Full Year 2025 Financial Results and Highlights Recent Activity

Other Events, Financial Statements or Exhibits

Material Definitive Agreement, Other Events, Financial Statements or Exhibits

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Additional info about upcoming vote

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission